YAP1 and breast cancer: Chen et al. showed that the leukaemia inhibitory factor receptor (LIFR) acts upstream the Hippo pathway, limiting oncogenic YAP transfer to the nucleus, and is downregulated in human breast cancer, which correlates with poor clinical conditions [16,17].